Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024

SAVA 10.31.2024

Full Press ReleaseSEC FilingsOur SAVA Tweets

About Gravity Analytica

Recent News

  • 01.07.2025 - Cassava Sciences Provides a Business Update
  • 01.06.2025 - Freda Nassif
  • 11.25.2024 - Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints

Recent Filings

  • 01.07.2025 - EX-99.1 EX-99.1
  • 01.07.2025 - 8-K Current report
  • 12.03.2024 - 4 Statement of changes in beneficial ownership of securities
PDF Version
Conference call and webcast to begin at 8:30 AM ET

AUSTIN, Texas,Oct. 31, 2024(GLOBE NEWSWIRE) --Cassava Sciences, Inc.(Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it will hold a conference call onThursday, November 7that8:30 a.m. Eastern Time.

Event details:
Date:Thursday, November 7th
Time:8:30 a.m. Eastern Time
Audio Webcast:https://www.CassavaSciences.com/company-presentations
Or
Audio Webcast:https://edge.media-server.com/mmc/p/tzb9j3sy

A replay of the audio webcast will also be available on the “Company Presentations” page of theCassava Scienceswebsite for 90 days following the webcast.

AboutCassava Sciences, Inc.Cassava Sciencesis a clinical-stage biotechnology company based inAustin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease.

Simufilam is Cassava Sciences’ small molecule oral drug candidate currently in Phase 3 clinical trials for the treatment of Alzheimer's disease. Simufilam targets a specific site on filamin A, a scaffolding protein that is critical to certain receptor interactions in the brain. Cassava Sciences believes that simufilam interrupts amyloid-β42 binding to receptors in the brain and may affect the Alzheimer's disease process.Cassava Sciencesowns exclusive, worldwide rights to its investigational product candidates and related technologies, without royalty obligations to any third party.

For more information, please visit:https://www.CassavaSciences.com

For More Information Contact:

InvestorsSandya van der Weidsvonderweid@lifesciadvisors.com

MediaSitrick And CompanyMike_Sitrick@Sitrick.com

CompanyEric Schoen, Chief Financial Officer(512) 501-2450ESchoen@CassavaSciences.com

Primary Logo

Source: Cassava Sciences, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com